Colgate-Palmolive Company (CL), the global consumer staples leader in oral care, personal care, home care, and pet nutrition through its Hill's Pet Nutrition business, trades near $84 a share. The question investors are asking is whether the stock can climb to the $100 mark, a level just above its recent 52-week high of about $99 and roughly in line with the consensus view of Wall Street analysts.
Colgate-Palmolive carries broad but not universal bullish coverage. Multiple independent data providers report a consensus "Buy" or "Moderate Buy" rating, with an average stock price target of roughly $98 to $99 based on polls of about 19 to 21 analysts. Independently reviewing individual, attributable targets — including recent figures from Piper Sandler ($95), Bernstein ($99), Barclays ($87), RBC Capital ($104), Bank of America ($102), UBS ($109), TD Cowen ($90), JPMorgan ($103), Deutsche Bank ($101), Morgan Stanley ($104), Wells Fargo ($95), Citigroup ($110), Evercore ISI ($100), and Goldman Sachs ($100) — yields a rounded mean near $100, within the widely reported $87-to-$110 range.
The dispersion matters as much as the midpoint. Bulls emphasize the company's 2030 growth plan, premiumization in oral care, and emerging-market reach, which supports targets above $100. Cautious analysts, including recent trims from BofA, RBC Capital, Piper Sandler, and Wells Fargo, point to oil-based input costs and a stretched valuation, keeping their targets near or below the current price. Notably, TD Cowen turned more cautious in late March, while Deutsche Bank moved the other way with an upgrade, underscoring that the analyst consensus is shifting rather than settled.
With the stock near $84 and a 52-week range of roughly $74.55 to $99.33, reaching $100 requires an increase of about 19%. That qualifies as a substantial move for a large-cap staples name that typically trades with low volatility (a five-year beta around 0.3). The path would likely depend less on a single catalyst and more on sustained earnings delivery: the company has beaten consensus EPS (earnings per share) estimates in recent quarters, including a second-quarter print of $0.99 versus a $0.95 estimate.
Fundamentals remain solid but not spectacular. Full-year 2026 revenue is expected to grow about 5%, with EPS forecast near $3.87 and next-year EPS near $4.10. At roughly 33 times trailing earnings and about 2.5% dividend yield, the stock is not cheap by historical standards, meaning upside may need to come from earnings growth and multiple stability rather than re-rating alone.
The stock's recent 52-week high near $99.33 serves as the most direct resistance level on the way to $100, with the round-number $100 mark itself acting as a psychological barrier. On the downside, the mid-$80s area, where the stock currently consolidates, is the first meaningful support level, followed by the low-$80s and the 52-week low near $74.55. The overall structure remains within a broad $75-to-$100 range, suggesting that a decisive break above prior highs would be needed to establish a new uptrend.
Analyst price targets generally reflect a research horizon of about 12 months, though individual analysts apply different assumptions about growth, margins, and multiples. Investors should watch quarterly earnings and guidance — the next report is scheduled for late October 2026 — along with commentary on input costs, gross margin, and emerging-market demand. Analyst revisions, foreign-exchange moves, and any shifts in the company's 2030 plan or restructuring progress will also be important signposts for the $100 path.
Traders seeking a more dynamic view of CL can complement fundamental research with AI Daily Buy/Sell Signals from Tickeron. This tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. It helps traders discover opportunities, monitor existing positions, and identify shifting trends more efficiently than manual screening alone.
Can Colgate-Palmolive stock reach $100? The target is credible — it sits essentially at the rounded average analyst price target and just above the recent 52-week high — but it is not a foregone conclusion. Reaching it would require roughly a 19% advance, a substantial move for a low-beta staples name. The bull case rests on pricing power, international growth, and disciplined margin management, while the bear case centers on cost inflation and a premium valuation that analysts continue to trim targets around. With targets spanning $87 to $110 and recent revisions moving in both directions, the honest answer is that $100 is achievable but dependent on continued earnings delivery and a stable cost environment. Investors should watch upcoming earnings, guidance, and analyst revisions rather than treat any single figure as a certainty.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, CL has been closely correlated with PG. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if CL jumps, then PG could also see price increases.